Ahmed M Shafter, Kashif Shaikh, Amit Johanis, Matthew J Budoff
{"title":"De-risking primary prevention: role of imaging.","authors":"Ahmed M Shafter, Kashif Shaikh, Amit Johanis, Matthew J Budoff","doi":"10.1177/17539447211051248","DOIUrl":null,"url":null,"abstract":"<p><p>Atherosclerotic cardiovascular disease (ASCVD) is a common disease among the general population, and includes four major areas: (1) coronary heart disease (CHD), manifested by stable angina, unstable angina, myocardial infarction (MI), heart failure, and coronary death; (2) cerebrovascular disease, manifested by transient ischemia attack and stroke; (3) peripheral vascular disease, manifested by claudication and critical limb ischemia; and (4) aortic atherosclerosis and aortic aneurysm (thoracic and abdominal). CHD remains the leading cause of death for both men and women in the United States. So, it is imperative to identify people at risk of CHD and provide appropriate medical treatment or intervention to prevent serious complications and outcomes including sudden cardiac death. Coronary artery calcification (CAC) is a marker of subclinical coronary artery disease. Therefore, coronary artery calcium score is an important screening method for Coronary artery disease (CAD). In this article, we performed a comprehensive review of current literatures and studies assessing the prognostic value of CAC for future cardiovascular disease (CVD) events. We searched PubMed, MEDLINE, Google Scholar, and Cochrane library. We also reviewed the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the assessment of CVD risk. A CAC score of zero corresponds to very low CVD event rates (∼1% per year) and hence a potent negative risk marker. This has been referred to as the 'power of zero' and affords the lowest risk of any method of risk calculation. It is now indicated in the 2018 ACC/AHA Cholesterol guidelines to be used to avoid statins for 5-10 years after a score of zero, and then re-assess the patient.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"15 ","pages":"17539447211051248"},"PeriodicalIF":2.6000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/3f/10.1177_17539447211051248.PMC8640319.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Cardiovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17539447211051248","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 2
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is a common disease among the general population, and includes four major areas: (1) coronary heart disease (CHD), manifested by stable angina, unstable angina, myocardial infarction (MI), heart failure, and coronary death; (2) cerebrovascular disease, manifested by transient ischemia attack and stroke; (3) peripheral vascular disease, manifested by claudication and critical limb ischemia; and (4) aortic atherosclerosis and aortic aneurysm (thoracic and abdominal). CHD remains the leading cause of death for both men and women in the United States. So, it is imperative to identify people at risk of CHD and provide appropriate medical treatment or intervention to prevent serious complications and outcomes including sudden cardiac death. Coronary artery calcification (CAC) is a marker of subclinical coronary artery disease. Therefore, coronary artery calcium score is an important screening method for Coronary artery disease (CAD). In this article, we performed a comprehensive review of current literatures and studies assessing the prognostic value of CAC for future cardiovascular disease (CVD) events. We searched PubMed, MEDLINE, Google Scholar, and Cochrane library. We also reviewed the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the assessment of CVD risk. A CAC score of zero corresponds to very low CVD event rates (∼1% per year) and hence a potent negative risk marker. This has been referred to as the 'power of zero' and affords the lowest risk of any method of risk calculation. It is now indicated in the 2018 ACC/AHA Cholesterol guidelines to be used to avoid statins for 5-10 years after a score of zero, and then re-assess the patient.
动脉粥样硬化性心血管疾病(ASCVD)是普通人群的常见病,主要包括四大领域:(1)冠心病(CHD),表现为稳定型心绞痛、不稳定型心绞痛、心肌梗死(MI)、心力衰竭和冠状动脉死亡;(2)脑血管疾病,表现为短暂性缺血发作和脑卒中;(3)周围血管疾病,表现为跛行和危急肢体缺血;(4)主动脉粥样硬化和主动脉瘤(胸腹)。冠心病仍然是美国男性和女性死亡的主要原因。因此,识别有冠心病风险的人群,并提供适当的医疗或干预,以防止严重的并发症和包括心源性猝死在内的后果,是至关重要的。冠状动脉钙化(CAC)是亚临床冠状动脉疾病的标志。因此,冠状动脉钙评分是冠状动脉疾病(CAD)的重要筛查方法。在本文中,我们对评估CAC对未来心血管疾病(CVD)事件的预后价值的现有文献和研究进行了全面的回顾。我们检索了PubMed, MEDLINE, Google Scholar和Cochrane图书馆。我们还回顾了2018年美国心脏病学会(ACC)/美国心脏协会(AHA)关于心血管疾病风险评估的指南。CAC评分为零对应于非常低的心血管事件发生率(每年约1%),因此是一个强有力的负风险标记。这被称为“零的力量”,提供了任何风险计算方法中最低的风险。现在,在2018年ACC/AHA胆固醇指南中指出,在得分为零后的5-10年内避免使用他汀类药物,然后重新评估患者。
期刊介绍:
The journal is aimed at clinicians and researchers from the cardiovascular disease field and will be a forum for all views and reviews relating to this discipline.Topics covered will include: ·arteriosclerosis ·cardiomyopathies ·coronary artery disease ·diabetes ·heart failure ·hypertension ·metabolic syndrome ·obesity ·peripheral arterial disease ·stroke ·arrhythmias ·genetics